Growth hormone rebound after cessation of sms 201-995 treatment in acromegaly.

Abstract

We studied a 42-year-old woman who had persistent active acromegaly despite conventional therapies. She was treated for 6 months with SMS 201-995. Her mean plasma growth hormone GH values decreased during treatment from 9.1 +/- 1.2 to 6.6 +/- 1.2 micrograms/L. One month after the withdrawal of SMS 201-995, the plasma GH level increased to 24.4 micrograms/L (P less than 0.001). This elevation was clinically silent and transitory, as GH levels decreased 8 months later to 6.9 +/- 1.3 micrograms/L. Furthermore, at the beginning of therapy, her intractable headache was completely relieved; however, it progressively resumed under therapy. In conclusion, cessation of SMS 201-995 may be followed in some acromegalic patients by a rebound of plasma GH levels. This rebound suggests that SMS 201-995 decreases GH levels by an inhibition of its release from the pituitary. Furthermore, SMS 201-995 may relieve intractable headache in some acromegalic patients, but tolerance to the analgesic effect may develop.

• Authors: L Charest, R Comtois, H Beauregard, O Serri
• Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (Can J Neurol Sci) Vol. 16 Issue 4 Pg. 442-5 (Nov 1989) ISSN: 0317-1671 [Print] England
• PMID: 2804808 (Publication Type: Case Reports, Journal Article)

Chemical References

• Prolactin
• Growth Hormone
• Octreotide

Topics

• Acromegaly (drug therapy, etiology)
• Adenoma (complications, surgery)
• Adult
• Female
• Growth Hormone (metabolism)
• Humans
• Octreotide (therapeutic use)
• Pituitary Neoplasms (complications, surgery)
• Prolactin (metabolism)